» Articles » PMID: 6847169

Cefsulodin Pharmacokinetics in Patients with Various Degrees of Renal Function

Overview
Specialty Pharmacology
Date 1983 Mar 1
PMID 6847169
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The pharmacokinetics of cefsulodin were characterized in 19 patients with different degrees of renal function after a single 500-mg, 30-min intravenous infusion. Six subjects had a creatinine clearance (Clcr) of greater than 100 ml min-1 (group I), eight had a Clcr of between 12 and 42 ml min-1 (group II), and five had a Clcr of less than 10 ml min-1 (group III). Nine plasma and four urine samples were collected in the first 36 h. The plasma concentration-time data were fitted to a two-compartment open model. The mean beta-phase half-life was 1.77, 6.37, and 10.12 h in groups I, II, and III, respectively. A significant decline in plasma clearance (Clp) was also noted between the three groups: 136 to 49.6 to 27.2 ml min-1 in groups I, II, and III, respectively. Steady-state volume of distribution was 0.26 liter kg-1, regardless of renal function. The observed linear relationship between Clp and Clcr (Clp = 24.09 + 0.765 Clcr; r = 0.9566) can be utilized to revise dosage schedules for patients with any degree of renal impairment. The nonrenal clearance of cefsulodin was also noted to be significantly lower in groups II and III than in group I. Further investigations will be necessary to elucidate the mechanism(s) responsible for the decrease in the nonrenal clearance of cefsulodin.

Citing Articles

Single-dose pharmacokinetics of cefsulodin in patients with cystic fibrosis.

Reed M, Stern R, Yamashita T, Ackers I, Myers C, Blumer J Antimicrob Agents Chemother. 1984; 25(5):579-81.

PMID: 6732226 PMC: 185590. DOI: 10.1128/AAC.25.5.579.


In vitro studies of investigational beta-lactams as possible therapy for Pseudomonas aeruginosa endocarditis.

Zar F, Kany Jr R Antimicrob Agents Chemother. 1985; 27(1):1-3.

PMID: 3920956 PMC: 176194. DOI: 10.1128/AAC.27.1.1.


Clinical pharmacokinetics of the third generation cephalosporins.

Balant L, Dayer P, Auckenthaler R Clin Pharmacokinet. 1985; 10(2):101-43.

PMID: 3888488 DOI: 10.2165/00003088-198510020-00001.


Guide to drug dosage in renal failure.

Bennett W Clin Pharmacokinet. 1988; 15(5):326-54.

PMID: 3060292 DOI: 10.2165/00003088-198815050-00005.


Increased renal clearance of cefsulodin due to higher glomerular filtration rate in cystic fibrosis.

Hedman A, Alvan G, Strandvik B, Arvidsson A Clin Pharmacokinet. 1990; 18(2):168-75.

PMID: 2180614 DOI: 10.2165/00003088-199018020-00006.


References
1.
Wagner H . [Total joint surfact replacement in the hip joint. Preliminary communication]. Arch Orthop Unfallchir. 1975; 82(2):101-6. View

2.
Welling P, Craig W, Kunin C . Prediction of drug dosage in patients with renal failure using data derived from normal subjects. Clin Pharmacol Ther. 1975; 18(1):45-52. DOI: 10.1002/cpt197518145. View

3.
Granneman G, Sennello L . Precise high-performance liquid chromatographic procedure for the determination of cefsulodin, a new antipseudomonal cephalosporin antibiotic, in plasma. J Pharm Sci. 1982; 71(10):1112-5. DOI: 10.1002/jps.2600711008. View

4.
Granneman G, Sennello L, Sonders R, Wynne B, THOMAS E . Cefsulodin kinetics in healthy subjects after intramuscular and intravenous injection. Clin Pharmacol Ther. 1982; 31(1):95-103. DOI: 10.1038/clpt.1982.15. View

5.
Gibson T, Granneman G, Kallal J, Sennello L . Cefsulodin kinetics in renal impairment. Clin Pharmacol Ther. 1982; 31(5):602-8. DOI: 10.1038/clpt.1982.84. View